Compare EOD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOD | BCYC |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 291.8M |
| IPO Year | N/A | 2019 |
| Metric | EOD | BCYC |
|---|---|---|
| Price | $6.22 | $3.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 112.5K | ★ 472.1K |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $3.33 |
| 52 Week High | $6.74 | $9.08 |
| Indicator | EOD | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 47.63 |
| Support Level | $5.92 | $3.37 |
| Resistance Level | $6.53 | $3.99 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 24.34 | 42.16 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.